Abstract
AbstractParkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Despite extensive research, the etiology of both familial and sporadic PD remains unclear. While most PD cases are sporadic, a significant minority are linked to genetic mutations, notably in the synuclein‐alpha (SNCA) and leucine‐rich repeat kinase 2 (LRRK2) genes. Animal models, such as Drosophila melanogaster (D. melanogaster), enable detailed study of these genetic mutations and their neurotoxic effects. Recent advancements in mass spectrometry‐based proteomics have enhanced our understanding of PD by facilitating comprehensive analysis of protein expression and interactions in mutant and wild‐type organisms, potentially revealing novel therapeutic targets. This review highlights the pivotal role of mass spectrometry‐based proteomics in advancing PD research, emphasizing the contributions of D. melanogaster models in identifying potential biomarkers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
